1-4 of 4
Fariba Saghafifar
Close
Sort by
Journal Articles

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Dong Li, MD, MS, Marisa H. Miceli, MD, Athanasios Fassas, MD, Raymond Thertulien, MD, PhD, Sabitha Rajan, Fariba Saghafifar, MD, Guido J. Tricot, MD, Bart Barlogie, MD
Journal: Blood
Blood (2004) 104 (11): 1159.
https://doi.org/10.1182/blood.V104.11.1159.1159
Published: 2004
Journal Articles

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Steve D. Strout, Laurie Jones-Jackson, MD, Ronald C. Walker, MD, Gary Purnell, MD, Jose A. Diaz, MD, Fariba Saghafifar, MD, Klaus A. Hollmig, MD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD
Journal: Blood
Blood (2004) 104 (11): 1160.
https://doi.org/10.1182/blood.V104.11.1160.1160
Published: 2004
Journal Articles

Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Li Dong, MD, MS, Fariba Saghafifar, MD, Giampaolo Talamo, MD, Klaus A. Hollmig, MD, Guido Tricot, MD, Bart Barlogie, MD, PhD.
Journal: Blood
Blood (2004) 104 (11): 935.
https://doi.org/10.1182/blood.V104.11.935.935
Published: 2004
Journal Articles

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

Clinical Trials & Observations
Maurizio Zangari, Eric Siegel, Bart Barlogie, Elias Anaissie, Fariba Saghafifar, Athanasios Fassas, Christopher Morris, Louis Fink, Guido Tricot
Journal: Blood
Blood (2002) 100 (4): 1168–1171.
https://doi.org/10.1182/blood-2002-01-0335
Published: 2002